[{"address1": "Building 12, Block B", "address2": "Phase II, Biobay Industrial Park 218 Sangtian Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 6262 6701", "website": "https://www.gracellbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell  acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.", "fullTimeEmployees": 314, "companyOfficers": [{"maxAge": 1, "name": "Dr. Wei  Cao BM, Ph.D.", "age": 63, "title": "Founder, Chairman & CEO", "yearBorn": 1959, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yili  Xie M.B.A., Ph.D.", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Samuel Suhua  Zhang M.B.A., Ph.D.", "age": 54, "title": "Chief Business Officer", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wendy  Li M.D.", "age": 63, "title": "Chief Medical Officer", "yearBorn": 1959, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Li", "title": "Executive Officer", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 2, "previousClose": 6.05, "open": 6.21, "dayLow": 6.155, "dayHigh": 6.55, "regularMarketPreviousClose": 6.05, "regularMarketOpen": 6.21, "regularMarketDayLow": 6.155, "regularMarketDayHigh": 6.55, "payoutRatio": 0.0, "beta": -0.784, "forwardPE": -9.411765, "volume": 571699, "regularMarketVolume": 571699, "averageVolume": 548932, "averageVolume10days": 463010, "averageDailyVolume10Day": 463010, "bid": 0.0, "ask": 0.0, "bidSize": 900, "askSize": 800, "marketCap": 613928960, "fiftyTwoWeekLow": 1.4, "fiftyTwoWeekHigh": 6.99, "fiftyDayAverage": 4.2918, "twoHundredDayAverage": 3.361875, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 1477611648, "profitMargins": 0.0, "floatShares": 181847730, "sharesOutstanding": 95926400, "sharesShort": 1014590, "sharesShortPriorMonth": 898734, "sharesShortPreviousMonthDate": 1698710400, "dateShortInterest": 1701302400, "sharesPercentSharesOut": 0.0106, "heldPercentInsiders": 0.16527, "heldPercentInstitutions": 0.56028, "shortRatio": 1.78, "shortPercentOfFloat": 0.017, "impliedSharesOutstanding": 68131000, "bookValue": 16.899, "priceToBook": 0.37872064, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -496980992, "trailingEps": -0.97, "forwardEps": -0.68, "enterpriseToEbitda": -2.899, "52WeekChange": 1.6769912, "SandP52WeekChange": 0.22199476, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GRCL", "underlyingSymbol": "GRCL", "shortName": "Gracell Biotechnologies Inc.", "longName": "Gracell Biotechnologies Inc.", "firstTradeDateEpochUtc": 1610116200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "54f05ed8-1760-3cc2-8994-445bae3df5e8", "messageBoardId": "finmb_604186415", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.4, "targetHighPrice": 20.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.71, "targetMedianPrice": 11.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 1707858048, "totalCashPerShare": 3.561, "ebitda": -509636992, "totalDebt": 115824000, "quickRatio": 7.442, "currentRatio": 7.732, "debtToEquity": 7.145, "returnOnAssets": -0.19406, "returnOnEquity": -0.31574, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "CNY", "trailingPegRatio": null}]